Skip to menu Skip to content Skip to footer
Associate Professor Peter Mollee
Associate Professor

Peter Mollee

Email: 

Overview

Background

Dr Mollee practices as a consultant haematologist in clinical and laboratory haematology at the Princess Alexandra Hospital and is Associate Professor with the University of Queensland Medical School.

Having trained in Brisbane and Toronto, Dr Mollee has developed an international reputation studying amyloidosis and the plasma cell dyscrasias. He holds appointments with the Medical Scientific Advisory Group of Myeloma Australia, Australian Amyloidosis Network, National Blood Cancer Taskforce and is a member of the AACB Monoclonal Gammopathy Working Group and the International Kidney & Monoclonal Gammopathy Research Group. He is a past Chairman of the Australasian Leukaemia and Lymphoma Group (ALLG) and current Chair of the Australian Amyloidosis Network. He heads the Myeloma Service as well as the Queensland Amyloidosis Centre which runs one of the few clinics in Australia dedicated exclusively to the care of patients with amyloidosis.

Availability

Associate Professor Peter Mollee is:
Available for supervision

Qualifications

  • Masters (Coursework) of Medical Science, University of Newcastle
  • Royal Australasian College of Physicians, Royal Australasian College of Physicians
  • Royal College of Pathologists of Australasia, Royal College of Pathologists of Australasia

Research impacts

The research of the Queensland Amyloidosis Centre aims to improved the diagnosis, monitoring and therapy of all types of amyloidosis. The Centre, in collaboration with Pathology Queensland and the Translational Research Institute, developed laser capture macrodisscution and tandem mass spectrometry analysis to accurately diagnosis the type of amyloidosis that patients have and have introuduced this assay into the clinical laboratory. Research to improve the diagnosis and monitoring of this rare disease has also assessed immunoglobulin free light chain assays, bone scintigraphy and novel radionuclide PET tracers. The Queensland Amyloidosis Centre maintains an active clinical trial program in amyloidosis therapies including both investigator-initiated and commercial studies.

Works

Search Professor Peter Mollee’s works on UQ eSpace

313 works between 1997 and 2024

1 - 20 of 313 works

2024

Conference Publication

Efficacy and Safety of Isatuximab, Pomalidomide and Dexamethasone in Relapsed AL Amyloidosis: Interim Results of the Isamyp Phase 2 Joint Study from the IFM and ALLG

Mollee, Peter, Huart, Antoine, Mortona, Olga, Queru, Kentin, Leyronnas, Cecile, Stephanie, Harel, Sidiqi, Hasib, Desport, Estelle, Vincent, Laure, Macro, Margaret, Manier, Salomon, Jacquet, Caroline, Morel, Pierre, Horvath, Noemi, Bender, Sebastien, Olombel, Guillaume, Pascal, Virginie, Corre, Jill, Bridoux, Frank, Jaccard, Arnaud and Roussel, Murielle (2024). Efficacy and Safety of Isatuximab, Pomalidomide and Dexamethasone in Relapsed AL Amyloidosis: Interim Results of the Isamyp Phase 2 Joint Study from the IFM and ALLG. 66th ASH Annual Meeting, San Diego, CA United States, 7-10 December 2024. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood-2024-204700

Efficacy and Safety of Isatuximab, Pomalidomide and Dexamethasone in Relapsed AL Amyloidosis: Interim Results of the Isamyp Phase 2 Joint Study from the IFM and ALLG

2024

Conference Publication

Treatment of First Relapse of Multiple Myeloma in Australia and New Zealand (ANZ): Treatment Patterns and Outcomes: An ANZ Myeloma and Related Diseases Registry (ANZ MRDR) Analysis

Gration, Betty, Wellard, Cameron, Moore, Elizabeth, Tan, Marianne, Murphy, Matthew, Lim, Kenneth J. C., Rowland, James, Hamad, Nada, Rajagopal, Rajeev, Mollee, Peter, Spencer, Andrew, Quach, Hang and McCaughan, Georgia (2024). Treatment of First Relapse of Multiple Myeloma in Australia and New Zealand (ANZ): Treatment Patterns and Outcomes: An ANZ Myeloma and Related Diseases Registry (ANZ MRDR) Analysis. 66th ASH Annual Meeting, San Diego, CA United States, 7-10 December 2024. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood-2024-201790

Treatment of First Relapse of Multiple Myeloma in Australia and New Zealand (ANZ): Treatment Patterns and Outcomes: An ANZ Myeloma and Related Diseases Registry (ANZ MRDR) Analysis

2024

Conference Publication

Integrating Chromosomal 1 Abnormalities into the Definition of High-Risk Multiple Myeloma: A Report from the Australian and New Zealand Myeloma and Related Diseases Registry

Lim, Kenneth J. C., Wellard, Cameron, Moore, Elizabeth, Gration, Betty, Augustson, Bradley, Mollee, Peter, Zhang, Jennifer, Wong Doo, Nicole, Ringkowski, Sabine, Bryant, Adam, Ninkovic, Slavisa, Hamad, Nada, McCaughan, Georgia, Kumar, Shaji, Spencer, Andrew and Quach, Hang (2024). Integrating Chromosomal 1 Abnormalities into the Definition of High-Risk Multiple Myeloma: A Report from the Australian and New Zealand Myeloma and Related Diseases Registry. 66th ASH Annual Meeting, San Diego, CA United States, 7-10 December 2024. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood-2024-207609

Integrating Chromosomal 1 Abnormalities into the Definition of High-Risk Multiple Myeloma: A Report from the Australian and New Zealand Myeloma and Related Diseases Registry

2024

Conference Publication

Impact of Socioeconomic Status on Utilisation of ASCT and Overall Survival in Multiple Myeloma: A Report from the Australian and New Zealand (ANZ) Myeloma and Related Diseases Registry (ANZ MRDR)

Gration, Betty, Wellard, Cameron, Moore, Elizabeth, Mollee, Peter, Kerridge, Ian H., Spencer, Andrew, Shetty, Anita, Baker, Bart, Forsyth, Cecily, Heenan, Jessica, McQuilten, Zoe K, Wood, Erica M. and McCaughan, Georgia (2024). Impact of Socioeconomic Status on Utilisation of ASCT and Overall Survival in Multiple Myeloma: A Report from the Australian and New Zealand (ANZ) Myeloma and Related Diseases Registry (ANZ MRDR). 66th ASH Annual Meeting, San Diego, CA United States, 7-10 December 2024. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood-2024-199451

Impact of Socioeconomic Status on Utilisation of ASCT and Overall Survival in Multiple Myeloma: A Report from the Australian and New Zealand (ANZ) Myeloma and Related Diseases Registry (ANZ MRDR)

2024

Conference Publication

Plasma Cell Enumeration By Manual and Automated Methods to Establish a Standard Pictorial Reference

Murali, Aarya, Tobin, Joshua W.D. and Mollee, Peter (2024). Plasma Cell Enumeration By Manual and Automated Methods to Establish a Standard Pictorial Reference. 66th ASH Annual Meeting, San Diego, CA United States, 7-10 December 2024. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood-2024-204199

Plasma Cell Enumeration By Manual and Automated Methods to Establish a Standard Pictorial Reference

2024

Journal Article

Presence of 1q21 gain and amplification may be associated with poorer outcomes in Daratumumab-treated Multiple Myeloma Patients

Lim, Kenneth J C, Wellard, Cameron, Moore, Elizabeth, Ninkovic, Slavisa, Chng, Wee Joo, Spencer, Andrew, Mollee, Peter, Hocking, Jay, Ho, P. Joy, Janowski, Wojt, Kim, Kihyun, McCaughan, Georgia, Dun, Karen, McQuilten, Zoe, Chen, Fiona and Quach, Hang (2024). Presence of 1q21 gain and amplification may be associated with poorer outcomes in Daratumumab-treated Multiple Myeloma Patients. Clinical Lymphoma Myeloma and Leukemia. doi: 10.1016/j.clml.2024.11.002

Presence of 1q21 gain and amplification may be associated with poorer outcomes in Daratumumab-treated Multiple Myeloma Patients

2024

Conference Publication

An individualised bone-targeted exercise intervention for people with multiple myeloma: study protocol of the MyeEx-impact randomised controlled trial

Chong, Jamie, Nicol, Jennifer, Beck, Belinda, Kay, Shelley, Hart, Nicolas, Carter, Daniel, Woodrow, Carmel, Cunningham, Brent, Farley, Morgan, Boytar, Alexander, Baguley, Brenton, Rose, Grace, Mollee, Peter and Skinner, Tina (2024). An individualised bone-targeted exercise intervention for people with multiple myeloma: study protocol of the MyeEx-impact randomised controlled trial. COSA's 51st Annual Scientific Meeting, Gold Coast, QLD, Australia, 13–15 November 2024. Chichester, West Sussex, United Kingdom: Wiley-Blackwell Publishing.

An individualised bone-targeted exercise intervention for people with multiple myeloma: study protocol of the MyeEx-impact randomised controlled trial

2024

Conference Publication

Comparing the outcomes of frail acute myeloid leukaemia patients undergoing systemic therapy to their fitter counterparts

Sia, Aaron, Chopra, Sakshi, Ling, Victoria, Hubbard, Ruth Eleanor, Mollee, Peter, Gordon, Emily and Hanjani, Leila Shafiee (2024). Comparing the outcomes of frail acute myeloid leukaemia patients undergoing systemic therapy to their fitter counterparts. COSA's 51st Annual Scientific Meeting, Gold Coast, QLD, Australia, 13–15 November 2024. Chichester, West Sussex, United Kingdom: Wiley-Blackwell. doi: 10.1111/ajco.14117

Comparing the outcomes of frail acute myeloid leukaemia patients undergoing systemic therapy to their fitter counterparts

2024

Conference Publication

Development of a self-reported frailty index - The SELFI

Sia, Aaron Din How, Mollee, Peter, Berry, Robyn, Ladwa, Rahul, Ling, Victoria, Fletcher, James, Gordon, Emily, Walpole, Euan, Hanjani, Leila Shafiee, Reid, Natasha, Simonsen, Camilla and Hubbard, Ruth Eleanor (2024). Development of a self-reported frailty index - The SELFI. COSA's 51st Annual Scientific Meeting, Gold Coast, QLD, Australia, 13-15 November 2024. Chichester, West Sussex, United Kingdom: Wiley-Blackwell. doi: 10.1111/ajco.14117

Development of a self-reported frailty index - The SELFI

2024

Journal Article

Catheter-Related Thrombosis in Adults with Cancer: A Secondary Analysis of a Prospective Randomised Controlled Trial

Hapgood, Greg, Hill, Kate, Okano, Satomi, Abro, Emad, Looke, David, Kennedy, Glen, Pavilion, Gilbert, Van Kuilenburg, Rosita, Geary, Alanna, Joubert, Warren, Eastgate, Melissa, Jones, Mark and Mollee, Peter (2024). Catheter-Related Thrombosis in Adults with Cancer: A Secondary Analysis of a Prospective Randomised Controlled Trial. Journal of Thrombosis and Haemostasis, 23 (2), 627-634. doi: 10.1016/j.jtha.2024.11.002

Catheter-Related Thrombosis in Adults with Cancer: A Secondary Analysis of a Prospective Randomised Controlled Trial

2024

Journal Article

Developing and validating a discrete-event simulation model of multiple myeloma disease outcomes and treatment pathways using a national clinical registry

Irving, Adam, Petrie, Dennis, Harris, Anthony, Fanning, Laura, Wood, Erica M., Moore, Elizabeth, Wellard, Cameron, Waters, Neil, Huynh, Kim, Augustson, Bradley, Cook, Gordon, Gay, Francesca, McCaughan, Georgia, Mollee, Peter, Spencer, Andrew and McQuilten, Zoe K. (2024). Developing and validating a discrete-event simulation model of multiple myeloma disease outcomes and treatment pathways using a national clinical registry. PLoS One, 19 (8 August) e0308812, e0308812. doi: 10.1371/journal.pone.0308812

Developing and validating a discrete-event simulation model of multiple myeloma disease outcomes and treatment pathways using a national clinical registry

2024

Journal Article

Daratumumab, cyclophosphamide, bortezomib and dexamethasone for non-transplant eligible myeloma (AMaRC 03-16)

Mollee, Peter, Reynolds, John, Janowski, Wojt, Quach, Hang, Campbell, Philip, Gibbs, Simon, Lee, Sophie, Lee, Edwin, Taylor, Kerry, Cochrane, Tara, Wallington-Gates, Craig, Kwok, Fiona, Weber, Nicholas, Kerridge, Ian, Weston, Helen, Ho, P. Joy, Leahy, Michael F, Horvath, Noemi and Spencer, Andrew (2024). Daratumumab, cyclophosphamide, bortezomib and dexamethasone for non-transplant eligible myeloma (AMaRC 03-16). Blood Advances, 8 (14), 3721-3730. doi: 10.1182/bloodadvances.2023012539

Daratumumab, cyclophosphamide, bortezomib and dexamethasone for non-transplant eligible myeloma (AMaRC 03-16)

2024

Journal Article

The impact of biomarkers of malignancy (<scp>IMWG SLiM</scp> criteria) in myeloma in a real‐world population: Clinical characteristics, therapy and outcomes from the Australian and New Zealand Myeloma and Related Diseases Registry (<scp>ANZ MRDR</scp>)

Ho, P. Joy, Moore, Elizabeth, Wellard, Cameron, Quach, Hang, Blacklock, Hilary, Harrrison, Simon J., MacDonald, Emma‐Jane, McQuilten, Zoe K., Wood, Erica M., Mollee, Peter and Spencer, Andrew (2024). The impact of biomarkers of malignancy (IMWG SLiM criteria) in myeloma in a real‐world population: Clinical characteristics, therapy and outcomes from the Australian and New Zealand Myeloma and Related Diseases Registry (ANZ MRDR). British Journal of Haematology, 205 (4), 1337-1345. doi: 10.1111/bjh.19624

The impact of biomarkers of malignancy (<scp>IMWG SLiM</scp> criteria) in myeloma in a real‐world population: Clinical characteristics, therapy and outcomes from the Australian and New Zealand Myeloma and Related Diseases Registry (<scp>ANZ MRDR</scp>)

2024

Journal Article

Carfilzomib, thalidomide, and dexamethasone is safe and effective in relapsed and/or refractory multiple myeloma: final report of the single arm, multicenter phase II ALLG MM018/AMN002 study

Ninkovic, Slavisa, Harrison, Simon J, Lee, Je-Jung, Murphy, Nick, Lee, Jae Hoon, Estell, Jane, Chen, Vivien M, Horvath, Noemi, Kim, Kihuyn, Eek, Richard, Augustson, Bradley, Bang, Soo-Mee, Huang, Shang-Yi, Rajagopal, Rajeev, Szabo, Ferenc, Engeler, Daniel, Butcher, Belinda E, Mollee, Peter, Durie, Brian, Chng, Wee Joo and Quach, Hang (2024). Carfilzomib, thalidomide, and dexamethasone is safe and effective in relapsed and/or refractory multiple myeloma: final report of the single arm, multicenter phase II ALLG MM018/AMN002 study. Haematologica, 109 (7), 2229-2238. doi: 10.3324/haematol.2023.284238

Carfilzomib, thalidomide, and dexamethasone is safe and effective in relapsed and/or refractory multiple myeloma: final report of the single arm, multicenter phase II ALLG MM018/AMN002 study

2024

Journal Article

Variation in immunoglobulin use and impact on survival in myeloma

Chai, Khai Li, Wellard, Cameron, Thao, LTP, Aoki, Naomi, Moore, Elizabeth M, Augustson, Bradley M, Bapat, Akshay, Blacklock, Hilary, Chng, Wee J, Cooke, Rachel, Forsyth, Cecily J, Goh, Yeow‐Tee, Hamad, Nada, Harrison, Simon J, Ho, P Joy, Hocking, Jay, Kerridge, Ian, Kim, Jin Seok, Kim, Kihyun, King, Tracy, McCaughan, Georgia J, Mollee, Peter, Morrissey, C Orla, Murphy, Nick, Quach, Hang, Tan, Xuan Ni, Tso, Allison CY, Wong, Kimberly SQ, Yoon, Sung‐Soo ... McQuilten, Zoe K (2024). Variation in immunoglobulin use and impact on survival in myeloma. eJHaem, 5 (4), 690-697. doi: 10.1002/jha2.938

Variation in immunoglobulin use and impact on survival in myeloma

2024

Journal Article

2024 Australia–New Zealand Expert Consensus Statement on Cardiac Amyloidosis

Bart, Nicole K., Fatkin, Diane, Gunton, James, Hare, James L., Korczyk, Dariusz, Kwok, Fiona, Lam, Kaitlyn, Russell, David, Sidiqi, Hasib, Sutton, Tim, Gibbs, Simon D.J., Mollee, Peter and Thomas, Liza (2024). 2024 Australia–New Zealand Expert Consensus Statement on Cardiac Amyloidosis. Heart, Lung and Circulation, 33 (4), 420-442. doi: 10.1016/j.hlc.2023.11.027

2024 Australia–New Zealand Expert Consensus Statement on Cardiac Amyloidosis

2024

Journal Article

Serum free light chain kinetics is predictive of renal response in myeloma patients with renal impairment– an ALLG trial of carfilzomib-dexamethasone therapy in frontline and relapse

Ho, P. Joy, Spencer, Andrew, Mollee, Peter, Bryant, Christian E., Enjeti, Anoop K., Horvath, Noemi, Butcher, Belinda E., Trotman, Judith, Gibbs, Simon and Joshua, Douglas E. (2024). Serum free light chain kinetics is predictive of renal response in myeloma patients with renal impairment– an ALLG trial of carfilzomib-dexamethasone therapy in frontline and relapse. Clinical Lymphoma Myeloma and Leukemia, 24 (8), 543-552.e1. doi: 10.1016/j.clml.2024.04.001

Serum free light chain kinetics is predictive of renal response in myeloma patients with renal impairment– an ALLG trial of carfilzomib-dexamethasone therapy in frontline and relapse

2024

Journal Article

Improving care for systemic light-chain amyloidosis patients: is a multidisciplinary approach best?

Ranjit Anderson, Nirija, Korczyk, Dariusz and Mollee, Peter (2024). Improving care for systemic light-chain amyloidosis patients: is a multidisciplinary approach best?. Expert Review of Hematology, 17 (9), 567-579. doi: 10.1080/17474086.2024.2388184

Improving care for systemic light-chain amyloidosis patients: is a multidisciplinary approach best?

2023

Conference Publication

Serial 18F-Florbetaben Positron Emission Tomography and Cardiac Magnetic Resonance Imaging in the Evaluation of Systemic Light Chain Cardiac Amyloidosis Enhances Diagnostic and Response Assessment Accuracy

Ranjit Anderson, Nirija, Law, W. Phillip, Dong, Xin, Ng, Arnold C.T and Mollee, Peter (2023). Serial 18F-Florbetaben Positron Emission Tomography and Cardiac Magnetic Resonance Imaging in the Evaluation of Systemic Light Chain Cardiac Amyloidosis Enhances Diagnostic and Response Assessment Accuracy. 65th ASH Annual Meeting, San Diego, CA United States, 9-12 December 2023. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood-2023-186377

Serial 18F-Florbetaben Positron Emission Tomography and Cardiac Magnetic Resonance Imaging in the Evaluation of Systemic Light Chain Cardiac Amyloidosis Enhances Diagnostic and Response Assessment Accuracy

2023

Conference Publication

Planned Interim Safety Analysis of the Phase 3 Randomized Trial of Selinexor and Lenalidomide Versus Lenalidomide Maintenance Post Autologous Stem Cell Transplant for Patients with Newly Diagnosed Multiple Myeloma (ALLG MM23; Sealand)

Quach, Hang, Lasica, Masa, Low, Michael, Mollee, Peter, Lai, Hock Choong, Wong Doo, Nicole, Hocking, Jay, Campbell, Philip, Murphy, Nicholas E., Sidiqi, M. Hasib, Routledge, David, Heenan, Jessica, Horvath, Noemi, Eek, Richard, Renwick, William E. P., Lenton, Douglas Stuart, Child, Lauren J, McCaughan, Georgia, Butcher, Belinda E, Mazumdar, Deepmala and Kalff, Anna (2023). Planned Interim Safety Analysis of the Phase 3 Randomized Trial of Selinexor and Lenalidomide Versus Lenalidomide Maintenance Post Autologous Stem Cell Transplant for Patients with Newly Diagnosed Multiple Myeloma (ALLG MM23; Sealand). 65th ASH Annual Meeting, San Diego, CA United States, 9-12 December 2023. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood-2023-185169

Planned Interim Safety Analysis of the Phase 3 Randomized Trial of Selinexor and Lenalidomide Versus Lenalidomide Maintenance Post Autologous Stem Cell Transplant for Patients with Newly Diagnosed Multiple Myeloma (ALLG MM23; Sealand)

Supervision

Availability

Associate Professor Peter Mollee is:
Available for supervision

Before you email them, read our advice on how to contact a supervisor.

Supervision history

Current supervision

Media

Enquiries

For media enquiries about Associate Professor Peter Mollee's areas of expertise, story ideas and help finding experts, contact our Media team:

communications@uq.edu.au